Delving into the Latest Updates on Puding Hewei Capsule with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Digestive System Disorders

Active Indication

Chronic nonatrophic gastritis

Inactive Indication-

Originator Organization-

Active Organization

Jiangxi Huiren Pharmaceutical Co., Ltd.The First Affiliated Hospital of Nanchang University

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

主要目的：初步评价患者连续服药14天后胃脘胀或（和）痛、口黏且苦症状消失率以及药物的安全性。次要目的: 初步评价连续14天患者中医症候疗效总有效率、幽门螺旋杆菌(Hp)清除率。为药物Ⅲ期临床研究方案的确定提供依据。

[Translation]

Primary purpose: To preliminarily evaluate the disappearance rate of epigastric distension or (and) pain, sticky and bitter mouth symptoms and the safety of the drug after patients took the drug for 14 consecutive days. Secondary purpose: To preliminarily evaluate the total effective rate of TCM symptoms and Helicobacter pylori (Hp) clearance rate of patients for 14 consecutive days. To provide a basis for the determination of the Phase III clinical research plan of the drug.

Start Date-

Sponsor / Collaborator

Jiangxi Huiren Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Puding Hewei Capsule

Login to view more data

100 Translational Medicine associated with Puding Hewei Capsule

Login to view more data

100 Patents (Medical) associated with Puding Hewei Capsule

Login to view more data

100 Deals associated with Puding Hewei Capsule

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic nonatrophic gastritis	Phase 2	China	Jiangxi Huiren Pharmaceutical Co., Ltd.	20 Mar 2019
Chronic nonatrophic gastritis	Phase 2	China	The First Affiliated Hospital of Nanchang University	20 Mar 2019